ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSION-Similar Outcomes After Matched Related and Unrelated Donor Transplant: A Study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon)

• Published in: Pediatric hematology and oncology Vol. 25; no. 4; pp. 245 - 259
• Main Authors: Muñoz, A., Diaz-Heredia, C., Diaz, M. A., Badell, I., Verdeguer, A., Martinez, A., Gomez, P., Perez-Hurtado, J. M., Bureo, E., Fernandez-Delgado, R., Gonzalez-Valentin, M. E., Maldonado, M. S.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01-01-2008; Taylor & Francis
• Subjects: acute lymphoblastic leukemia; Adolescent; allogeneic; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease - mortality; Graft vs Host Disease - prevention & control; Hematopoietic Stem Cell Transplantation - mortality; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Quality of Life; Recurrence; related donor; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; unrelated donor
• ISSN: 0888-0018; 1521-0669
• DOI: 10.1080/08880010802016557

The authors report the results of 58 children with ALL in 2CR after related (n = 31) or unrelated (n = 27) AHSCT. Characteristics at diagnosis and initial and after relapse antileukemic treatment were similar in the related donor (RD) and the unrelated donor (UD) groups. Conditioning consisted of TBI/CY ± VP-16 for patients ≥3 years old (n = 43) and Bu/CY for the rest. Median recipient age was 8 years (range 1-17) in the RD and 9 years (range 3-14) in the UD group. Median follow-up was 54 months (range 24-80) and 52 months (range 22-85) in the RD and the UD groups repectively.The 5-year EFS probability was 43 ± 9% for the RD group and 36 ± 9% in the UD group (p =. 25). The transplant-related mortality was 16% in the RD and 37% in the UD group (p =. 016). In the RD group 36.7% of patients relapsed versus 18.6% in the UD group (p =. 05). GvHD associated with organ failure or infection caused most of the transplant-related deaths in both groups. Survivor quality of life for both groups was good (Lansky score ≤ 90).